YourChoice Therapeutics develops a non-hormonal contraceptive product. Its technology is based on the “molecular condom” concept: the active compound inhibits vigorous sperm motility and prevents sperm from fertilizing the egg.
ALICE Technologies is the developer of an AI-powered construction simulation platform. It leverages artificial intelligence to analyze a project's complex building requirements, generate efficient building schedules, and tune those schedules as needed during construction. The company's platform enables contractors and owners to plan, bid, and build more effectively, reducing construction times and labor costs by $30 million for a typical $500 million construction project. ALICE Technologies works with construction leaders in the infrastructure and commercial construction segments, such as Parsons, HDCC, and Kajima Corporation.
Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists to advance new evidence-based medicine that helps people living with moderate to severe mental health conditions. For more information, please visit osmind.org.
64x Bio builds a platform that increases the speed and scale of mammalian cell line discovery. The company uses a throughput discovery and screening platform and an integrated computational design loop, they develop new ways of generating highly optimized and otherwise unattainable cell lines for the manufacturing of viral vectors, with a specific focus on those used for cell and gene therapies.
Faeth Therapeutics is a data-driven, evidence-based company that specializes in mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment. It fully focuses on matching specific diets with tumor genotypes and treatment regimens to improve the outcomes of cancer therapy. The company was founded to translate breakthrough discoveries, made by cancer research laboratories, into clinical practice. Its founding team includes some of the industry’s preeminent researchers and clinicians.
Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives. Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. Gameto aims to change that. Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, they have developed a platform to produce female reproductive cell lines. They use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Their team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Gameto's first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno.
Ockam is simple. There are three things you need to know: First, we enable you to build trust between every application, database, SaaS service, code repo, data lake, AI Engine, container, and microservice... everywhere, in any network. Second, Ockam is networkless. We enable you to skip the pain of system administration, IP Backlogs, Allow Lists, VPNs, firewalls, reverse proxies, setting up public endpoints, creating public APIs, and key administration. And third, Ockam is secure-by-design. It is open-source, audited and built in rust. It does the encryption, authentication, key generation, rotation, revocation, and a lot more. For more information, please visit www.ockam.io.
Woola uses leftover sheep wool to replace bubble wrap. These wool-based packages can be reused, repurposed, or returned by the end user, with the ultimate goal of making the solution “closed-loop” so nothing goes to waste.
New Culture is a food and beverage company that focuses on revolutionizing how cheese is made. It was founded in 2018 and headquartered in San Francisco, California.
Cambrian Biopharma is a multi-asset biotech R&D firm uniquely focused on a specific field of biomedical research: the biology of aging, also known as geroscience. We believe the future of medicine should be proactive and committed to extending our best years, not just reactive to certain diseases. As experts in the biology of age-related disease, it is our mission to assemble the world's best scientists to accelerate this paradigm shift. We are built on an emerging business model we call a "Distributed R&D Company" (or "DisCo"), partnering with academic geroscientists to build companies, conduct preclinical drug discovery, and manage clinical trials. Cambrian looks to discover and develop therapeutics that target the molecular damage that arises during aging and leads to chronic disease. Our approach is to build a diverse portfolio led by scientific rigor and data, not ego. Focusing on early-stage therapeutics, we collaborate with pioneering scientists to bring discoveries out of the lab and into the clinic as efficiently as possible. So far, we have launched 10 companies with leading geroscientists and have relationships with more than 100 geroscience-focused labs globally, translating to a toolkit for tech-transfer negotiations and rapid spinouts.
Earthshot Labs brings together investors, carbon buyers, and land stewards in an AI powered platform to finance ecological restoration projects that are equitable for local communities.
Hum Capital is the funding platform that connects great companies with the right capital. Hum offers companies raising up to $50 million the most efficient, transparent path to growth. Hum’s Intelligent Capital Market uses AI to translate volumes of a company’s financial data into the clearest picture of their value, so they can fundraise with confidence, on the best terms for their business. Investors on Hum’s platform gain investment insights and a personalized deal flow built on company data they can trust. For more information, visit HumCapital.com.
Latent AI accelerates AI implementation and workflows for the enterprise cost-effectively anywhere on the edge continuum with Adaptive AI.
Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists to advance new evidence-based medicine that helps people living with moderate to severe mental health conditions. For more information, please visit osmind.org.
Beeflow applies scientific knowledge and technologies to bee pollination. Providing professional pollination services to farmers increases crop yields while reducing bee population decline. Since first started 4 years ago in Argentina, the company has increased between 20-90% crop yields in Blueberries, Almonds, Raspberries, and Kiwifruit.
MobileCoin is a cryptocurrency platform that develops P2P payment tokens and digital payment systems for mobile. It combines privacy, security, and distributed trust with a great user experience. MobileCoin is designed so that a mobile messaging application like WhatsApp, Facebook Messenger, or Signal could integrate with a MobileCoin wallet.
Cambrian Biopharma is a multi-asset biotech R&D firm uniquely focused on a specific field of biomedical research: the biology of aging, also known as geroscience. We believe the future of medicine should be proactive and committed to extending our best years, not just reactive to certain diseases. As experts in the biology of age-related disease, it is our mission to assemble the world's best scientists to accelerate this paradigm shift. We are built on an emerging business model we call a "Distributed R&D Company" (or "DisCo"), partnering with academic geroscientists to build companies, conduct preclinical drug discovery, and manage clinical trials. Cambrian looks to discover and develop therapeutics that target the molecular damage that arises during aging and leads to chronic disease. Our approach is to build a diverse portfolio led by scientific rigor and data, not ego. Focusing on early-stage therapeutics, we collaborate with pioneering scientists to bring discoveries out of the lab and into the clinic as efficiently as possible. So far, we have launched 10 companies with leading geroscientists and have relationships with more than 100 geroscience-focused labs globally, translating to a toolkit for tech-transfer negotiations and rapid spinouts.
Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies. The company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need. They are also focused on the discovery, development, and delivery of medicines that alter the treatment landscape and contributing value to patients and society. Sensei Biotherapeutics using its proprietary drug discovery platform to study and understand the tumor microenvironment and identify a new class of cancer immunotherapies that act through new biology and differentiated mechanisms. It brings together scientific leaders in biology, immunology, and oncology along with a highly experienced management team and scientific advisors. The company's platform, ImmunoPhage enables the generation of immune-activating agents that fully engage activation of both the innate and adaptive immune systems. Sensei Biotherapeutics is headquartered in Gaithersburg, Maryland with an office in Boston, MA, USA.
Atai Life Sciences is a biotechnology company that develops therapies for mental health disorders. The company focuses on creating treatments using psychedelic compounds and other methods to address conditions such as depression, anxiety, and substance use disorders. Atai collaborates with various partners and research institutions to advance its drug development pipeline, which includes several clinical-stage programs. The product portfolio includes therapies that utilize research in psychedelics and neuroscience. Atai's lead programs feature ketamine-based treatments and other compounds aimed at improving mental well-being. The company works with experts in the field to ensure the efficacy and safety of its therapies. Atai Life Sciences has received recognition for its work in mental health treatment, securing partnerships and funding to support its research initiatives. The company has been acknowledged for its contributions to psychiatry and has gained attention for its efforts to advance the understanding and treatment of mental health disorders.
ALICE Technologies is the developer of an AI-powered construction simulation platform. It leverages artificial intelligence to analyze a project's complex building requirements, generate efficient building schedules, and tune those schedules as needed during construction. The company's platform enables contractors and owners to plan, bid, and build more effectively, reducing construction times and labor costs by $30 million for a typical $500 million construction project. ALICE Technologies works with construction leaders in the infrastructure and commercial construction segments, such as Parsons, HDCC, and Kajima Corporation.
Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies. The company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need. They are also focused on the discovery, development, and delivery of medicines that alter the treatment landscape and contributing value to patients and society. Sensei Biotherapeutics using its proprietary drug discovery platform to study and understand the tumor microenvironment and identify a new class of cancer immunotherapies that act through new biology and differentiated mechanisms. It brings together scientific leaders in biology, immunology, and oncology along with a highly experienced management team and scientific advisors. The company's platform, ImmunoPhage enables the generation of immune-activating agents that fully engage activation of both the innate and adaptive immune systems. Sensei Biotherapeutics is headquartered in Gaithersburg, Maryland with an office in Boston, MA, USA.
Taimei Technology is a Digital Innovator in the R&D and Life Science Industry. Taimei has developed an industry-leading, successfully deployed integrated digital platform that is dedicated to clinical research with in-depth insights into drug R&D, pharmacovigilance, marketing & sales and market access. Our unified digital platform integrates advanced AI, big data, cloud computing and mobile Internet technologies to provide innovative solutions to the industry stakeholders across the full product life cycle. Taimei Technology is building the infrastructure for the future of the life science industry to accelerate product launches, improve quality, enhance drug safety, improve drug accessibility and reduce the medical burden on patients and providers.
Hum Capital is the funding platform that connects great companies with the right capital. Hum offers companies raising up to $50 million the most efficient, transparent path to growth. Hum’s Intelligent Capital Market uses AI to translate volumes of a company’s financial data into the clearest picture of their value, so they can fundraise with confidence, on the best terms for their business. Investors on Hum’s platform gain investment insights and a personalized deal flow built on company data they can trust. For more information, visit HumCapital.com.
Commonwealth Fusion is a research company that develops energy through an inexhaustible power plant. It uses rare-earth barium copper oxide superconductor technology to develop energy. They combine proven physics backed by decades of government-funded fusion research with a revolutionary superconducting magnet technology to accelerate the path to commercial fusion energy Commonwealth Fusion Systems (CFS) is on track to bring fusion energy technology to the market. CFS was spun out of MIT and is collaborating with MIT’s Plasma Science and Fusion Center to leverage decades of research combined with the innovation and speed of the private sector. The business designs and builds fusion machines that deliver limitless and clean fusion energy and integrate proven physics with magnet technology, allowing clients to contribute to the expansion of renewable energy while mitigating the effects of climate change.
Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI.
Hum Capital is the funding platform that connects great companies with the right capital. Hum offers companies raising up to $50 million the most efficient, transparent path to growth. Hum’s Intelligent Capital Market uses AI to translate volumes of a company’s financial data into the clearest picture of their value, so they can fundraise with confidence, on the best terms for their business. Investors on Hum’s platform gain investment insights and a personalized deal flow built on company data they can trust. For more information, visit HumCapital.com.
Ockam is simple. There are three things you need to know: First, we enable you to build trust between every application, database, SaaS service, code repo, data lake, AI Engine, container, and microservice... everywhere, in any network. Second, Ockam is networkless. We enable you to skip the pain of system administration, IP Backlogs, Allow Lists, VPNs, firewalls, reverse proxies, setting up public endpoints, creating public APIs, and key administration. And third, Ockam is secure-by-design. It is open-source, audited and built in rust. It does the encryption, authentication, key generation, rotation, revocation, and a lot more. For more information, please visit www.ockam.io.
The Boring Company is an infrastructure and tunnel construction company that facilitates underground transportation networks. It aims to create safe, fast-to-dig, and low-cost transportation, utility, and freight tunnels.
Commonwealth Fusion is a research company that develops energy through an inexhaustible power plant. It uses rare-earth barium copper oxide superconductor technology to develop energy. They combine proven physics backed by decades of government-funded fusion research with a revolutionary superconducting magnet technology to accelerate the path to commercial fusion energy Commonwealth Fusion Systems (CFS) is on track to bring fusion energy technology to the market. CFS was spun out of MIT and is collaborating with MIT’s Plasma Science and Fusion Center to leverage decades of research combined with the innovation and speed of the private sector. The business designs and builds fusion machines that deliver limitless and clean fusion energy and integrate proven physics with magnet technology, allowing clients to contribute to the expansion of renewable energy while mitigating the effects of climate change.
Latent AI accelerates AI implementation and workflows for the enterprise cost-effectively anywhere on the edge continuum with Adaptive AI.
Mythic Inc. is a technology company that specializes in designing and developing silicon chips and artificial intelligence (AI) processing units. Founded in 2012 and headquartered in Redwood City, California, with an office in Austin, Texas, Mythic focuses on creating analog matrix processors that enable AI capabilities across a range of devices, from fitness bands and hearing aids to self-driving cars and robotic drones. The company’s flagship products include the M1076 Analog Matrix Processor and various PCIe and M.2 cards. Mythic's technology integrates hybrid digital and analog computations within flash arrays, providing desktop-grade compute power in a compact form factor while maintaining performance, energy efficiency, and accuracy. The company has assembled a diverse team of experts in neural networks, software design, and processor architecture to advance AI deployment in real-world environments.
Medcorder helps patients record, store, transcribe, and share their physician encounters in order to better understand what their doctors are telling them. The app is designed for patients and their families to better communicate and coordinate care in order to achieve better outcomes and to help bring to bear the best from all in a patient's inner circle, even those far away. With an aging population that is widely distributed, the majority of the elderly do not have nearby adult children to assist with their care in the event of a complex condition such as cancer. Medcorder believes that they can achieve better outcomes for patients with better informally-gathered at-home charting and by helping patients get the right data in the hands of medical professionals at the right time.